Randomized Trials Meet Real-World Evidence in the Era of Combination CKD Therapies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Chronic kidney disease (CKD) in type 2 diabetes (T2D) is no longer managed with a single therapeutic option. Instead, treatment increasingly relies on layered combination of renin–angiotensin system inhibitors (RASi), sodium–glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (nsMRA), and an expanding group of cardio-kidney-metabolic (CKM) therapies.1-4 Clinical practice guidelines have evolved rapidly as randomized trials have demonstrated the benefits of these agents, and defining these as guideline-directed medical therapies (GDMTs) in CKD and T2D.
Fields of Study & Subjects
Chronic Kidney Disease and Diabetes
Diabetes Treatment and Management
Acute Kidney Injury Research
Publication details
- Journal / source
- Kidney International Reports
- Volume
- 11
- Issue
- 5
- Pages
- 106519–106519
- Publication date
- 30 March 2026
- Language
- EN